Topic: Calreticulin

Relapsing remitting multiple sclerosis (RRMS) hits around 85% MS patients. The main disease modifying therapies (DMTs) of this subtype are: Fingolimod (Gilenya), IFN-β A1(Rebif & Avonex), Teriflunomide(Aubagio), IFN-β 1B(β-feron) and Dimethyl Fumarate(Marovarex).The study aimed at: 1.Expression profiling of long non-coding RNA MALAT-1 in RRMS patients, MALAT1 knockdown and evaluating successful silencing of MALAT1 by specific siRNAs, 2.Expression profiling of Inflammasome components in RRMS patients and studying the impact of MALAT1-knock down on them, 3.Expression profiling of Calreticuli

Microglia continuously remodel synapses, which are embedded in the extracellular matrix (ECM). However, the mechanisms which govern this process remain elusive. To investigate the influence of the neural ECM in synaptic remodeling by microglia, we disrupted ECM integrity by injection of chondroitinase ABC (ChABC) into the retrosplenial cortex of healthy adult mice. Using in vivo two-photon microscopy we found that ChABC treatment increased microglial branching and ECM phagocytic capacity and decreased spine elimination rate under basal conditions. Moreover, ECM attenuation largely prevented sy